All Online

1 - 12 of 29 results

Refine

Active filters

Diabetes Mellitus, Type 2
1.25 CME CREDITS

This activity is part of the ConnectED Learning: Diabetes curriculum. It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic live educational program will feature renowned faculty experts who will lead an interactive discussion on important evidence supporting emerging clinical strategies, shared decision making, and ways in which to individualize care to best manage the complex challenges of diabetes and the progression of disease. It will include therapeutic approaches that can reduce the risks such as hypoglycemia, weight gain, and cardiovascular events.


1 CME CREDIT

This activity is part of the ConnectED Learning: Diabetes curriculum. Join expert faculty as they address your remaining questions and provide a distillation of clinical pearls from the ConnectED Learning Curriculum on the management of diabetes


0.56 CME CREDIT

This activity is part of the ConnectED Learning: Diabetes curriculum. In this Expert Perspective, Dr. Richard Pratley outlines the main facets of utilizing oral combination therapy to intensify treatment in order to achieve HbA1c goals while minimizing side effects and cardiovascular risk.


1 CME CREDIT

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin analogs are essential antihyperglycemic therapies for many patients with type 2 diabetes mellitus (T2DM) (eg, those in need of large glucose-lowering effects or, based on recent updates to the official indications for 2 of the GLP-1 RAs). This Engaging the Patient activity will discuss newer insulin therapies as well as GLP-1 injectable therapies, including rationales and clinical trial evidence for combining these two agents. The activity includes a demonstration of clinician and patient interactions-ways to educate patients on the use of injectable medications, as well as approaches to reducing hypoglycemia and improving patient adherence.


0.57 CME CREDIT

This case outlines nuances of intensifying therapy with oral antidiabetic agents based on patient and disease characteristics


0.57 CME CREDIT

This activity is part of the ConnectED Learning: Diabetes curriculum. This case will highlight best practices of intensifying therapy with oral combination regimens in individuals with T2DM.


0.78 CME CREDIT

Follow the complex case of a 55-year-old patient who presents with long-standing, uncontrolled type 2 diabetes requiring individualized care. Filled with common scenarios relevant to primary care, this case distinguishes nuances in management based on patient- and disease-specific factors while enhancing your knowledge on the myriad diabetes therapies available today.


1.5 CME CREDITS

Through real-time interaction with faculty, learners will evaluate the differences between conventional and newer basal insulins and review the clinical impact of hypoglycemia, as well as the strategies for detecting, preventing, and managing hypoglycemia.


1.57 CME CREDITS

Insulin therapy is more complicated than ever. This important session will teach you how to leverage the many choices of basal, short- and rapid-acting, and premixed insulins, and how to combine them with noninsulin therapies in order to optimize glycemic control, improve adherence, and reduce the risk of hypoglycemia. We will also review new insulin formulations in development and discuss overcoming barriers to injectable therapies.


0.58 CME CREDIT

This case discusses treatment intensification with the combination of a GLP-1 RA and basal insulin in a patient with uncontrolled T2DM. Treatment decisions will include individualized HbA1c guideline recommendations, patient preference, cardiovascular risk, and other comorbidities such as visual impairment.


0.75 CME CREDIT

In this case presentation, Dr. Mathioudakis shares strategies for treatment intensification while minimizing the risk of hypoglycemia and highlights the differences between conventional and newer basal insulin products. He also describes how to appropriately initiate and dose newer basal insulin products in patients with type 2 diabetes.